Treatment Pattern of Oral Anticoagulants (OAC) in Japan

Treatment Patterns of Newly Initiated Oral Anticoagulants on Japanese Non-valvular Atrial Fibrillation Patients Using a Japanese Claims Database

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02982863

Enrollment

48696

Registered

2016-12-06

Start date

2016-12-01

Completion date

2016-12-01

Last updated

2018-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

1. To understand the treatment patterns of OACs and baseline patient characteristics of Japanese Non-Valvular Atrial Fibrillation (NVAF) patients 2. To determine whether warfarin and dabigatran new user group can be balanced using propensity score matching using pre-specified baseline covariates. 3. As an exploratory analysis, to assess mean duration of on-therapy follow-up time in database

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients aged \>18 year-old with confirmed diagnosis of NVAF (ICD 10 code I48), being new starters of either dabigatran, warfarin, apixaban or edoxaban, having no prescription of other OACs for12 months prior to the index date (defined as the first prescription of OACs (the period is defined as baseline period)), and having an index date between 14 Mar 2011 to 30 June 2016

Exclusion criteria

* Patients having less than 12 months of enrolment prior to the index date , being dialysis or kidney transplant recipients in baseline period, having either atrial flutter, valvular AF, mechanical valve placement, rheumatic AF, and/or mitral valve prolapse/regurge/stenosis in baseline period, and having record of deep vein thrombosis or pulmonary embolism \< 6 months before Atrial Fibrillation (AF) diagnosis in baseline period

Design outcomes

Primary

Measure	Time frame	Description
Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF	Day 1	Number of patients by each type of study-target OAC drug (dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban) prescribed as the first Oral Anticoagulants (OAC) with Non-valvular atrial fibrillation (NVAF)
Number of Patients Prescribed OAC Drug Dabigatran by Dosage	Day 1	Number of patients prescribed OAC drug dabigatran at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Number of Patients Prescribed OAC Drug Warfarin by Dosage	Day 1	Number of patients prescribed OAC drug Warfarin at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	Day 1	Number of patients prescribed OAC drug rivaroxaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Number of Patients Prescribed OAC Drug Apixaban by Dosage	Day 1	Number of patients prescribed OAC drug Apixaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.
Number of Patients Prescribed OAC Drug Edoxaban by Dosage	Day 1	Number of patients prescribed OAC drug edoxaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.

Secondary

Measure	Time frame	Description
Baseline Characteristics: AF Risk Score	Day 1	Baseline characteristics of patients in each treatment group: Atrial Fibrillation (AF) risk score CHADS2: Congestive heart failure, Hypertension, Age, Diabetes, Stroke(doubled). CHADS2 score range from 0-6, with higher scores indicating the higher risk CHA2DS2VASc: Cardiac failure or dysfunction, Hypertension, Age 75 (doubled), Diabetes, Stroke (doubled) Vascular disease, Age 65-74 and Sex category (female) score. CHA2DS2VASc score range from 1-9, with higher scores indicating the higher risk. HAS-BLED: Hypertension, Abnormal renal function, Abnormal hepatic function. HAS-BLED score range from 0-8, with higher scores indicating the higher risk.
Baseline Characteristics: Age	1 day	Baseline characteristics of patients in each treatment group: age
Baseline Characteristics: Concomitant Medication	Day 1	Baseline characteristics of patients in each treatment group: concomitant medication
Baseline Characteristics: Gender	Day 1	Baseline characteristics of patients in each treatment group: gender
Baseline Characteristics: Year of Initiating Treatment	Day 1	Baseline characteristics of patients in each treatment group: year of initiating treatment
Baseline Characteristics: Speciality of Prescribers of OAC	Day 1	Baseline characteristics of patients in each treatment group: speciality of prescribers of OAC. int.= internal; Med.= Medicine
Baseline Characteristics: History of Disease	Day 1	Baseline characteristics of patients in each treatment group: history of disease and hospitalization.
Baseline Characteristics: History of Hospitalization	Day 1	Baseline characteristics: history of hospitalization

Countries

Japan

Participant flow

Recruitment details

A retrospective, observational study using health insurance claims data.48696 patients were prescribed dabigatran, warfarin, apixaban, edoxaban, or rivaroxaban as the first OACs but 50 patients were removed as they took more than one these drugs. Thus only 48646 patients were prescribed the drugs of interest.

Pre-assignment details

The Japanese patients diagnosed as Non-Valvular Atrial Fibrillation (NVAF) between April 2010 and June 2016, were prescribed dabigatran, warfarin, apixaban, edoxaban, or rivaroxaban as the first OACs. DPC; Diagnosis Procedure Combination (DPC)

Participants by arm

Arm	Count
Dabigatran Patients prescribed dabigatran as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.	4,936
Warfarin Patients prescribed warfarin as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.	12,484
Apixaban Patients prescribed Apixaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.	11,386
Rivaroxaban Patients prescribed Rivaroxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.	8,758
Edoxaban Patients prescribed Edoxaban as the first Oral Anticoagulants (OACs) with nonvalvular atrial fibrillation.	2,268
Total	39,832

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004
Overall Study	Not eligible patients	809	4,261	1,852	1,400	492

Baseline characteristics

Characteristic	Dabigatran	Warfarin	Apixaban	Rivaroxaban	Edoxaban	Total
Age, Continuous	72 Years STANDARD_DEVIATION 10	78 Years STANDARD_DEVIATION 10	77 Years STANDARD_DEVIATION 10	74 Years STANDARD_DEVIATION 11	77 Years STANDARD_DEVIATION 10	76 Years STANDARD_DEVIATION 10
Sex: Female, Male Female	1625 Participants	5068 Participants	4737 Participants	3183 Participants	1130 Participants	15743 Participants
Sex: Female, Male Male	3311 Participants	7416 Participants	6649 Participants	5575 Participants	1138 Participants	24089 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0
serious Total, serious adverse events	0 / 0	0 / 0	0 / 0	0 / 0	0 / 0

Outcome results

Primary

Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF

Number of patients by each type of study-target OAC drug (dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban) prescribed as the first Oral Anticoagulants (OAC) with Non-valvular atrial fibrillation (NVAF)

Time frame: Day 1

Population: Patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF	4936 Participants
Warfarin	Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF	12484 Participants
Apixaban	Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF	11386 Participants
Rivaroxaban	Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF	8758 Participants
Edoxaban	Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF	2268 Participants

Primary

Number of Patients Prescribed OAC Drug Apixaban by Dosage

Number of patients prescribed OAC drug Apixaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	1.25 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	2.5 mg	428 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	3.75 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	5 mg	6300 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	7.5 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	10 mg	4789 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	15 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	20 mg	27 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	25 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Apixaban by Dosage	35 mg	1 Participants

Primary

Number of Patients Prescribed OAC Drug Dabigatran by Dosage

Number of patients prescribed OAC drug dabigatran at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Number of Patients Prescribed OAC Drug Dabigatran by Dosage	75 milligram (mg)	58 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Dabigatran by Dosage	110 mg	164 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Dabigatran by Dosage	150 mg	354 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Dabigatran by Dosage	220 mg	3343 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Dabigatran by Dosage	225 mg	5 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Dabigatran by Dosage	300 mg	1072 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Dabigatran by Dosage	440 mg	1 Participants

Primary

Number of Patients Prescribed OAC Drug Edoxaban by Dosage

Number of patients prescribed OAC drug edoxaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Number of Patients Prescribed OAC Drug Edoxaban by Dosage	15 mg	279 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Edoxaban by Dosage	30 mg	1594 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Edoxaban by Dosage	60 mg	412 Participants

Primary

Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage

Number of patients prescribed OAC drug rivaroxaban at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	5 mg	14 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	7.5 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	9.9 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	9.99 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	10 mg	4372 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	10.005 mg	4 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	10.05 mg	10 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	10.5 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	15 mg	4340 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	20 mg	5 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	22.5 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage	30 mg	72 Participants

Primary

Number of Patients Prescribed OAC Drug Warfarin by Dosage

Number of patients prescribed OAC drug Warfarin at the index date by dosage. If a patient had more than one prescriptions of an OAC at the day, the patient was multiple-counted.

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.002 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.006 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.125 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.2 mg	4 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.25 mg	338 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.3 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.374 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.5 mg	1726 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.6 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.625 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.65 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.7 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.75 mg	256 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.8 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.875 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	0.9 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1 mg	3125 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.2 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.25 mg	62 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.3 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.5 mg	630 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.55 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.7 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.75 mg	66 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.8 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	1.9 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	2 mg	4711 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	2.2 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	2.25 mg	54 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	2.3 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	2.4 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	2.5 mg	462 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	2.7 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	2.75 mg	24 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	3 mg	1913 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	3.2 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	3.25 mg	17 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	3.3 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	3.5 mg	128 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	3.7 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	3.75 mg	9 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	4 mg	421 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	4.25 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	4.5 mg	41 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	4.6 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	4.75 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	5 mg	468 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	5.5 mg	9 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	6 mg	25 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	6.5 mg	2 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	7 mg	8 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	7.75 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	8 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	9 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	10 mg	16 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	17.5 mg	1 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	20 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	30 mg	12 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	40 mg	3 Participants
Dabigatran	Number of Patients Prescribed OAC Drug Warfarin by Dosage	50 mg	1 Participants

Secondary

Baseline Characteristics: AF Risk Score

Baseline characteristics of patients in each treatment group: Atrial Fibrillation (AF) risk score CHADS2: Congestive heart failure, Hypertension, Age, Diabetes, Stroke(doubled). CHADS2 score range from 0-6, with higher scores indicating the higher risk CHA2DS2VASc: Cardiac failure or dysfunction, Hypertension, Age 75 (doubled), Diabetes, Stroke (doubled) Vascular disease, Age 65-74 and Sex category (female) score. CHA2DS2VASc score range from 1-9, with higher scores indicating the higher risk. HAS-BLED: Hypertension, Abnormal renal function, Abnormal hepatic function. HAS-BLED score range from 0-8, with higher scores indicating the higher risk.

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Baseline Characteristics: AF Risk Score	8 (CHA2DS2VASc)	96 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	0 (CHA2DS2VASc)	198 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	3 (HAS-BLED)	1192 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	9 (CHA2DS2VASc)	14 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	2 (HAS-BLED)	1616 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	0 (HAS-BLED)	297 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	5 (CHADS2)	243 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	1 (HAS-BLED)	1276 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	2 (CHADS2)	1131 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	1 (CHA2DS2VASc)	547 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	1 (CHADS2)	1103 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	2 (CHA2DS2VASc)	878 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	4 (CHADS2)	582 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	0 (CHADS2)	707 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	3 (CHA2DS2VASc)	968 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	6 (CHADS2)	117 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	8 (HAS-BLED)	0 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	4 (CHA2DS2VASc)	916 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	7 (HAS-BLED)	1 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	5 (CHA2DS2VASc)	690 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	6 (HAS-BLED)	7 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	6 (CHA2DS2VASc)	441 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	5 (HAS-BLED)	89 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	7 (CHA2DS2VASc)	188 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	3 (CHADS2)	1053 Participants
Dabigatran	Baseline Characteristics: AF Risk Score	4 (HAS-BLED)	458 Participants
Warfarin	Baseline Characteristics: AF Risk Score	4 (HAS-BLED)	1562 Participants
Warfarin	Baseline Characteristics: AF Risk Score	3 (CHA2DS2VASc)	2380 Participants
Warfarin	Baseline Characteristics: AF Risk Score	3 (HAS-BLED)	3738 Participants
Warfarin	Baseline Characteristics: AF Risk Score	7 (CHA2DS2VASc)	738 Participants
Warfarin	Baseline Characteristics: AF Risk Score	8 (HAS-BLED)	0 Participants
Warfarin	Baseline Characteristics: AF Risk Score	9 (CHA2DS2VASc)	67 Participants
Warfarin	Baseline Characteristics: AF Risk Score	0 (CHA2DS2VASc)	182 Participants
Warfarin	Baseline Characteristics: AF Risk Score	2 (HAS-BLED)	4180 Participants
Warfarin	Baseline Characteristics: AF Risk Score	6 (CHA2DS2VASc)	1482 Participants
Warfarin	Baseline Characteristics: AF Risk Score	3 (CHADS2)	3458 Participants
Warfarin	Baseline Characteristics: AF Risk Score	0 (HAS-BLED)	245 Participants
Warfarin	Baseline Characteristics: AF Risk Score	4 (CHA2DS2VASc)	2685 Participants
Warfarin	Baseline Characteristics: AF Risk Score	1 (HAS-BLED)	2303 Participants
Warfarin	Baseline Characteristics: AF Risk Score	6 (CHADS2)	508 Participants
Warfarin	Baseline Characteristics: AF Risk Score	2 (CHADS2)	2816 Participants
Warfarin	Baseline Characteristics: AF Risk Score	7 (HAS-BLED)	0 Participants
Warfarin	Baseline Characteristics: AF Risk Score	5 (HAS-BLED)	403 Participants
Warfarin	Baseline Characteristics: AF Risk Score	1 (CHA2DS2VASc)	585 Participants
Warfarin	Baseline Characteristics: AF Risk Score	4 (CHADS2)	1897 Participants
Warfarin	Baseline Characteristics: AF Risk Score	1 (CHADS2)	2239 Participants
Warfarin	Baseline Characteristics: AF Risk Score	8 (CHA2DS2VASc)	369 Participants
Warfarin	Baseline Characteristics: AF Risk Score	5 (CHA2DS2VASc)	2496 Participants
Warfarin	Baseline Characteristics: AF Risk Score	2 (CHA2DS2VASc)	1500 Participants
Warfarin	Baseline Characteristics: AF Risk Score	5 (CHADS2)	816 Participants
Warfarin	Baseline Characteristics: AF Risk Score	0 (CHADS2)	750 Participants
Warfarin	Baseline Characteristics: AF Risk Score	6 (HAS-BLED)	53 Participants
Apixaban	Baseline Characteristics: AF Risk Score	1 (CHADS2)	2504 Participants
Apixaban	Baseline Characteristics: AF Risk Score	5 (CHADS2)	626 Participants
Apixaban	Baseline Characteristics: AF Risk Score	6 (CHADS2)	378 Participants
Apixaban	Baseline Characteristics: AF Risk Score	0 (CHA2DS2VASc)	280 Participants
Apixaban	Baseline Characteristics: AF Risk Score	1 (CHA2DS2VASc)	773 Participants
Apixaban	Baseline Characteristics: AF Risk Score	2 (CHA2DS2VASc)	1692 Participants
Apixaban	Baseline Characteristics: AF Risk Score	3 (CHA2DS2VASc)	2213 Participants
Apixaban	Baseline Characteristics: AF Risk Score	4 (CHA2DS2VASc)	2216 Participants
Apixaban	Baseline Characteristics: AF Risk Score	5 (CHA2DS2VASc)	2070 Participants
Apixaban	Baseline Characteristics: AF Risk Score	6 (CHA2DS2VASc)	1165 Participants
Apixaban	Baseline Characteristics: AF Risk Score	7 (CHA2DS2VASc)	644 Participants
Apixaban	Baseline Characteristics: AF Risk Score	8 (CHA2DS2VASc)	257 Participants
Apixaban	Baseline Characteristics: AF Risk Score	9 (CHA2DS2VASc)	76 Participants
Apixaban	Baseline Characteristics: AF Risk Score	0 (HAS-BLED)	422 Participants
Apixaban	Baseline Characteristics: AF Risk Score	1 (HAS-BLED)	2848 Participants
Apixaban	Baseline Characteristics: AF Risk Score	2 (HAS-BLED)	3725 Participants
Apixaban	Baseline Characteristics: AF Risk Score	3 (HAS-BLED)	2837 Participants
Apixaban	Baseline Characteristics: AF Risk Score	4 (HAS-BLED)	1258 Participants
Apixaban	Baseline Characteristics: AF Risk Score	5 (HAS-BLED)	266 Participants
Apixaban	Baseline Characteristics: AF Risk Score	6 (HAS-BLED)	30 Participants
Apixaban	Baseline Characteristics: AF Risk Score	7 (HAS-BLED)	0 Participants
Apixaban	Baseline Characteristics: AF Risk Score	8 (HAS-BLED)	0 Participants
Apixaban	Baseline Characteristics: AF Risk Score	0 (CHADS2)	1150 Participants
Apixaban	Baseline Characteristics: AF Risk Score	2 (CHADS2)	2330 Participants
Apixaban	Baseline Characteristics: AF Risk Score	3 (CHADS2)	2787 Participants
Apixaban	Baseline Characteristics: AF Risk Score	4 (CHADS2)	1611 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	0 (CHA2DS2VASc)	295 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	3 (HAS-BLED)	2159 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	7 (CHA2DS2VASc)	402 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	4 (HAS-BLED)	872 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	6 (CHA2DS2VASc)	769 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	6 (CHADS2)	258 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	5 (HAS-BLED)	162 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	5 (CHA2DS2VASc)	1348 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	4 (CHADS2)	1014 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	6 (HAS-BLED)	20 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	4 (CHA2DS2VASc)	1718 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	3 (CHADS2)	2005 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	7 (HAS-BLED)	1 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	3 (CHA2DS2VASc)	1735 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	8 (HAS-BLED)	0 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	2 (CHA2DS2VASc)	1481 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	0 (CHADS2)	1072 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	1 (CHA2DS2VASc)	783 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	1 (CHADS2)	1928 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	0 (HAS-BLED)	432 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	5 (CHADS2)	459 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	1 (HAS-BLED)	2228 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	9 (CHA2DS2VASc)	39 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	2 (CHADS2)	2022 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	2 (HAS-BLED)	2884 Participants
Rivaroxaban	Baseline Characteristics: AF Risk Score	8 (CHA2DS2VASc)	188 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	0 (HAS-BLED)	68 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	8 (HAS-BLED)	0 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	3 (HAS-BLED)	590 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	7 (CHA2DS2VASc)	129 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	2 (CHA2DS2VASc)	305 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	6 (CHADS2)	85 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	9 (CHA2DS2VASc)	17 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	4 (HAS-BLED)	270 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	6 (CHA2DS2VASc)	241 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	5 (CHADS2)	125 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	8 (CHA2DS2VASc)	61 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	0 (CHADS2)	238 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	5 (HAS-BLED)	46 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	5 (CHA2DS2VASc)	380 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	1 (CHA2DS2VASc)	140 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	2 (HAS-BLED)	746 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	4 (CHADS2)	267 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	6 (HAS-BLED)	3 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	4 (CHA2DS2VASc)	432 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	1 (HAS-BLED)	545 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	1 (CHADS2)	513 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	0 (CHA2DS2VASc)	66 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	7 (HAS-BLED)	0 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	3 (CHA2DS2VASc)	497 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	2 (CHADS2)	517 Participants
Edoxaban	Baseline Characteristics: AF Risk Score	3 (CHADS2)	523 Participants

Secondary

Baseline Characteristics: Age

Baseline characteristics of patients in each treatment group: age

Time frame: 1 day

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Value (MEAN)	Dispersion
Dabigatran	Baseline Characteristics: Age	72 Years	Standard Deviation 10
Warfarin	Baseline Characteristics: Age	78 Years	Standard Deviation 10
Apixaban	Baseline Characteristics: Age	77 Years	Standard Deviation 10
Rivaroxaban	Baseline Characteristics: Age	74 Years	Standard Deviation 11
Edoxaban	Baseline Characteristics: Age	77 Years	Standard Deviation 10

Secondary

Baseline Characteristics: Concomitant Medication

Baseline characteristics of patients in each treatment group: concomitant medication

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Baseline Characteristics: Concomitant Medication	Aspirin	989 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Procainamide	14 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Pilsicainide	582 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Disopyramide	102 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Proton pump inhibitor	1869 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Flecainide	130 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Cilostazole	199 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Statins	1029 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Clopidogrel	346 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	H2 receptor antagonist	761 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Diuretics	1277 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	ARB or ACE	1649 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Ticlodipine	69 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Digoxin	506 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Beta blocker	1779 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Calcium channel blockers (CCB)	2176 Participants
Dabigatran	Baseline Characteristics: Concomitant Medication	Amiodarone	62 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Beta blocker	4376 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Diuretics	5901 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Procainamide	40 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Proton pump inhibitor	5512 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Ticlodipine	179 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Flecainide	105 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Calcium channel blockers (CCB)	5755 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Disopyramide	230 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	ARB or ACE	4773 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Aspirin	2848 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Digoxin	1959 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Cilostazole	522 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	H2 receptor antagonist	2559 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Statins	2736 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Pilsicainide	726 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Amiodarone	388 Participants
Warfarin	Baseline Characteristics: Concomitant Medication	Clopidogrel	1049 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Pilsicainide	970 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Aspirin	2027 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Ticlodipine	115 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Cilostazole	466 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Clopidogrel	1031 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	ARB or ACE	3650 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Beta blocker	4272 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Amiodarone	301 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Procainamide	43 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Disopyramide	180 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Flecainide	237 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Calcium channel blockers (CCB)	5148 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Digoxin	944 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Diuretics	3698 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Statins	2364 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	Proton pump inhibitor	4583 Participants
Apixaban	Baseline Characteristics: Concomitant Medication	H2 receptor antagonist	1673 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Procainamide	17 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Amiodarone	138 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Pilsicainide	885 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Beta blocker	3137 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Calcium channel blockers (CCB)	3955 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	ARB or ACE	2954 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Digoxin	896 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Clopidogrel	767 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Aspirin	1621 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Diuretics	2480 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Cilostazole	306 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Statins	1876 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Ticlodipine	95 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	H2 receptor antagonist	1365 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Disopyramide	150 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Proton pump inhibitor	3506 Participants
Rivaroxaban	Baseline Characteristics: Concomitant Medication	Flecainide	150 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Flecainide	33 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Diuretics	681 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Cilostazole	66 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Pilsicainide	145 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Beta blocker	768 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Disopyramide	34 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Proton pump inhibitor	970 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	H2 receptor antagonist	367 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Calcium channel blockers (CCB)	955 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	ARB or ACE	661 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Amiodarone	31 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Aspirin	377 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Statins	407 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Digoxin	134 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Clopidogrel	153 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Ticlodipine	12 Participants
Edoxaban	Baseline Characteristics: Concomitant Medication	Procainamide	8 Participants

Secondary

Baseline Characteristics: Gender

Baseline characteristics of patients in each treatment group: gender

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Baseline Characteristics: Gender	Male	3311 Participants
Dabigatran	Baseline Characteristics: Gender	Female	1625 Participants
Warfarin	Baseline Characteristics: Gender	Male	7416 Participants
Warfarin	Baseline Characteristics: Gender	Female	5068 Participants
Apixaban	Baseline Characteristics: Gender	Male	6649 Participants
Apixaban	Baseline Characteristics: Gender	Female	4737 Participants
Rivaroxaban	Baseline Characteristics: Gender	Female	3183 Participants
Rivaroxaban	Baseline Characteristics: Gender	Male	5575 Participants
Edoxaban	Baseline Characteristics: Gender	Male	1138 Participants
Edoxaban	Baseline Characteristics: Gender	Female	1130 Participants

Secondary

Baseline Characteristics: History of Disease

Baseline characteristics of patients in each treatment group: history of disease and hospitalization.

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Baseline Characteristics: History of Disease	Kidney impairment	199 Participants
Dabigatran	Baseline Characteristics: History of Disease	Myocardial infarction	317 Participants
Dabigatran	Baseline Characteristics: History of Disease	Dyslipidemia	1366 Participants
Dabigatran	Baseline Characteristics: History of Disease	Stroke or transient ischemic attack	63 Participants
Dabigatran	Baseline Characteristics: History of Disease	Diabetes mellitus	1979 Participants
Dabigatran	Baseline Characteristics: History of Disease	Leukemia	34 Participants
Dabigatran	Baseline Characteristics: History of Disease	Coronary artery disease	39 Participants
Dabigatran	Baseline Characteristics: History of Disease	Valvular disease	1659 Participants
Dabigatran	Baseline Characteristics: History of Disease	Solid tumor cancer	1501 Participants
Dabigatran	Baseline Characteristics: History of Disease	Malignant lymphoma	62 Participants
Dabigatran	Baseline Characteristics: History of Disease	Dementia	107 Participants
Dabigatran	Baseline Characteristics: History of Disease	Heart failure	1899 Participants
Dabigatran	Baseline Characteristics: History of Disease	Bleeding (gastrointestinal, etc.)	1619 Participants
Dabigatran	Baseline Characteristics: History of Disease	Liver disease	784 Participants
Dabigatran	Baseline Characteristics: History of Disease	Peptic ulcer disease	958 Participants
Dabigatran	Baseline Characteristics: History of Disease	Peripheral artery disease	580 Participants
Dabigatran	Baseline Characteristics: History of Disease	Arterial hypertension	2938 Participants
Warfarin	Baseline Characteristics: History of Disease	Kidney impairment	697 Participants
Warfarin	Baseline Characteristics: History of Disease	Liver disease	1777 Participants
Warfarin	Baseline Characteristics: History of Disease	Valvular disease	4294 Participants
Warfarin	Baseline Characteristics: History of Disease	Bleeding (gastrointestinal, etc.)	3867 Participants
Warfarin	Baseline Characteristics: History of Disease	Heart failure	6750 Participants
Warfarin	Baseline Characteristics: History of Disease	Diabetes mellitus	4804 Participants
Warfarin	Baseline Characteristics: History of Disease	Dyslipidemia	2888 Participants
Warfarin	Baseline Characteristics: History of Disease	Arterial hypertension	8501 Participants
Warfarin	Baseline Characteristics: History of Disease	Myocardial infarction	903 Participants
Warfarin	Baseline Characteristics: History of Disease	Peripheral artery disease	1538 Participants
Warfarin	Baseline Characteristics: History of Disease	Peptic ulcer disease	2301 Participants
Warfarin	Baseline Characteristics: History of Disease	Dementia	447 Participants
Warfarin	Baseline Characteristics: History of Disease	Stroke or transient ischemic attack	145 Participants
Warfarin	Baseline Characteristics: History of Disease	Malignant lymphoma	171 Participants
Warfarin	Baseline Characteristics: History of Disease	Leukemia	161 Participants
Warfarin	Baseline Characteristics: History of Disease	Coronary artery disease	87 Participants
Warfarin	Baseline Characteristics: History of Disease	Solid tumor cancer	3830 Participants
Apixaban	Baseline Characteristics: History of Disease	Arterial hypertension	6990 Participants
Apixaban	Baseline Characteristics: History of Disease	Peripheral artery disease	1290 Participants
Apixaban	Baseline Characteristics: History of Disease	Myocardial infarction	890 Participants
Apixaban	Baseline Characteristics: History of Disease	Bleeding (gastrointestinal, etc.)	3567 Participants
Apixaban	Baseline Characteristics: History of Disease	Peptic ulcer disease	2148 Participants
Apixaban	Baseline Characteristics: History of Disease	Kidney impairment	527 Participants
Apixaban	Baseline Characteristics: History of Disease	Dementia	348 Participants
Apixaban	Baseline Characteristics: History of Disease	Solid tumor cancer	3413 Participants
Apixaban	Baseline Characteristics: History of Disease	Valvular disease	2961 Participants
Apixaban	Baseline Characteristics: History of Disease	Malignant lymphoma	159 Participants
Apixaban	Baseline Characteristics: History of Disease	Stroke or transient ischemic attack	128 Participants
Apixaban	Baseline Characteristics: History of Disease	Liver disease	1576 Participants
Apixaban	Baseline Characteristics: History of Disease	Diabetes mellitus	4255 Participants
Apixaban	Baseline Characteristics: History of Disease	Coronary artery disease	79 Participants
Apixaban	Baseline Characteristics: History of Disease	Dyslipidemia	3109 Participants
Apixaban	Baseline Characteristics: History of Disease	Heart failure	5099 Participants
Apixaban	Baseline Characteristics: History of Disease	Leukemia	107 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Stroke or transient ischemic attack	85 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Leukemia	82 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Bleeding (gastrointestinal, etc.)	2677 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Kidney impairment	360 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Solid tumor cancer	2524 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Peripheral artery disease	933 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Heart failure	3580 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Malignant lymphoma	109 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Coronary artery disease	53 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Arterial hypertension	5357 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Peptic ulcer disease	1558 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Myocardial infarction	629 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Valvular disease	2561 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Liver disease	1257 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Dyslipidemia	2402 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Dementia	268 Participants
Rivaroxaban	Baseline Characteristics: History of Disease	Diabetes mellitus	3324 Participants
Edoxaban	Baseline Characteristics: History of Disease	Bleeding (gastrointestinal, etc.)	782 Participants
Edoxaban	Baseline Characteristics: History of Disease	Stroke or transient ischemic attack	21 Participants
Edoxaban	Baseline Characteristics: History of Disease	Myocardial infarction	178 Participants
Edoxaban	Baseline Characteristics: History of Disease	Coronary artery disease	25 Participants
Edoxaban	Baseline Characteristics: History of Disease	Heart failure	977 Participants
Edoxaban	Baseline Characteristics: History of Disease	Diabetes mellitus	841 Participants
Edoxaban	Baseline Characteristics: History of Disease	Dyslipidemia	597 Participants
Edoxaban	Baseline Characteristics: History of Disease	Arterial hypertension	1344 Participants
Edoxaban	Baseline Characteristics: History of Disease	Peripheral artery disease	252 Participants
Edoxaban	Baseline Characteristics: History of Disease	Peptic ulcer disease	452 Participants
Edoxaban	Baseline Characteristics: History of Disease	Dementia	90 Participants
Edoxaban	Baseline Characteristics: History of Disease	Malignant lymphoma	41 Participants
Edoxaban	Baseline Characteristics: History of Disease	Leukemia	27 Participants
Edoxaban	Baseline Characteristics: History of Disease	Solid tumor cancer	678 Participants
Edoxaban	Baseline Characteristics: History of Disease	Kidney impairment	118 Participants
Edoxaban	Baseline Characteristics: History of Disease	Liver disease	339 Participants
Edoxaban	Baseline Characteristics: History of Disease	Valvular disease	615 Participants

Secondary

Baseline Characteristics: History of Hospitalization

Baseline characteristics: history of hospitalization

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Baseline Characteristics: History of Hospitalization	2384 Participants
Warfarin	Baseline Characteristics: History of Hospitalization	9494 Participants
Apixaban	Baseline Characteristics: History of Hospitalization	6517 Participants
Rivaroxaban	Baseline Characteristics: History of Hospitalization	4589 Participants
Edoxaban	Baseline Characteristics: History of Hospitalization	1412 Participants

Secondary

Baseline Characteristics: Speciality of Prescribers of OAC

Baseline characteristics of patients in each treatment group: speciality of prescribers of OAC. int.= internal; Med.= Medicine

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Internal medicine	1689 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Psychodiagnosis medical	2 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Hemodialysis	1 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Neuropathic internal medicine	210 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Nephrology	13 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Gastrointestinal	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry & neurology	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes	3 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Dermatology	9 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterology	106 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular internal medicine	444 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Urology	31 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory medicine	36 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Gynecology	2 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology & medical Oncology	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiology	1457 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Palliative care	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Allergy	1 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric cardiology	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Rheumatology	7 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology	6 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Breast and thyroid surgery	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatrics	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry	9 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Comprehensive medical care	13 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Surgery	109 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Oncotherapy	2 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Orthopedics	113 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Stroke	2 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Plastic surgery	5 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Connective tissue disease & iheumatic int. med.	2 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Cranial nerve surgery	319 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Unknown	27 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Large intestine and proctology	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Thoracic surgery	10 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Neurology	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes medicine	4 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular surgery	87 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Hepato-biliarypancreatic surgery	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric surgery	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Anesthesiology	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Digestive surgery	6 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Obstetrics and gynecology	4 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterological medicine	53 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Ophthalmology	19 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology & metabolism	1 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Emergency medicine	18 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Otorhinolaryngology	8 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory	66 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology	8 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Rehabilitation	30 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Metabolism internal medicine	0 Participants
Dabigatran	Baseline Characteristics: Speciality of Prescribers of OAC	Radiology	4 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Oncotherapy	6 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Ophthalmology	38 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Hemodialysis	8 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology	24 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Orthopedics	550 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Neuropathic internal medicine	410 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry & neurology	0 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Nephrology	85 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Anesthesiology	7 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Stroke	6 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Gastrointestinal	17 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric surgery	0 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes	14 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Emergency medicine	59 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Plastic surgery	21 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Dermatology	41 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Unknown	59 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular internal medicine	1258 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Connective tissue disease & iheumatic int. med.	8 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Digestive surgery	25 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Urology	161 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterology	283 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory medicine	161 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory	180 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Cranial nerve surgery	668 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Gynecology	2 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Radiology	12 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Psychodiagnosis medical	3 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology & medical Oncology	1 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Metabolism internal medicine	3 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Large intestine and proctology	1 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiology	2447 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Internal medicine	4316 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Palliative care	1 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Obstetrics and gynecology	11 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology & metabolism	1 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Allergy	9 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology	27 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric cardiology	3 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Thoracic surgery	58 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterological medicine	270 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Rheumatology	11 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes medicine	19 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Breast and thyroid surgery	3 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Otorhinolaryngology	47 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Rehabilitation	127 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatrics	5 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular surgery	405 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Comprehensive medical care	56 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Neurology	1 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Hepato-biliarypancreatic surgery	4 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Surgery	514 Participants
Warfarin	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry	38 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gynecology	1 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Internal medicine	3943 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychodiagnosis medical	2 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry	30 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Neurology	7 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory	95 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterology	100 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiology	2610 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Allergy	1 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Rheumatology	6 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatrics	4 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Surgery	202 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Orthopedics	212 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Plastic surgery	10 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cranial nerve surgery	932 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Thoracic surgery	27 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular surgery	115 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric surgery	1 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Obstetrics and gynecology	9 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Ophthalmology	26 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Otorhinolaryngology	25 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Rehabilitation	86 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Radiology	8 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Neuropathic internal medicine	518 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastrointestinal	5 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Dermatology	23 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Urology	76 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory medicine	112 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular internal medicine	1930 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes	8 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Nephrology	27 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hemodialysis	0 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Metabolism internal medicine	4 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology	16 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Emergency medicine	54 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterological medicine	61 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Digestive surgery	7 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hepato-biliarypancreatic surgery	4 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes medicine	12 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Large intestine and proctology	0 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Connective tissue disease & iheumatic int. med.	1 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Stroke	5 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Oncotherapy	0 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Comprehensive medical care	12 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Breast and thyroid surgery	0 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric cardiology	0 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Palliative care	0 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology & medical Oncology	1 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry & neurology	1 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology & metabolism	2 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Unknown	38 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology	11 Participants
Apixaban	Baseline Characteristics: Speciality of Prescribers of OAC	Anesthesiology	6 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Surgery	175 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular surgery	147 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Oncotherapy	1 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Neurology	3 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hepato-biliarypancreatic surgery	1 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatrics	4 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Emergency medicine	46 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Comprehensive medical care	9 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Otorhinolaryngology	19 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Thoracic surgery	25 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Rheumatology	3 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychodiagnosis medical	1 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Breast and thyroid surgery	2 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Metabolism internal medicine	7 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes medicine	9 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Allergy	0 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Anesthesiology	4 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric cardiology	0 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Obstetrics and gynecology	5 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Internal medicine	2816 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiology	2268 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology	20 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Palliative care	0 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cranial nerve surgery	654 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry	20 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterology	125 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Large intestine and proctology	0 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gynecology	2 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterological medicine	85 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology	15 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Urology	55 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology & medical Oncology	1 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory medicine	75 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Plastic surgery	5 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Rehabilitation	86 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Dermatology	23 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric surgery	0 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular internal medicine	1218 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Connective tissue disease & iheumatic int. med.	1 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology & metabolism	1 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastrointestinal	3 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Digestive surgery	10 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes	10 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Orthopedics	178 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Unknown	83 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Neuropathic internal medicine	415 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory	72 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Nephrology	15 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Stroke	0 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry & neurology	0 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Radiology	5 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Ophthalmology	36 Participants
Rivaroxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hemodialysis	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastrointestinal	1 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Rehabilitation	12 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Metabolism internal medicine	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Otorhinolaryngology	5 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Neurology	2 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology	2 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Ophthalmology	5 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Emergency medicine	11 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Obstetrics and gynecology	6 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterological medicine	20 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric surgery	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Digestive surgery	4 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular surgery	54 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Endocrinology & metabolism	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hepato-biliarypancreatic surgery	1 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Thoracic surgery	3 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry	7 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes medicine	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cranial nerve surgery	164 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Large intestine and proctology	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Plastic surgery	2 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Anesthesiology	1 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychiatry & neurology	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Connective tissue disease & iheumatic int. med.	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Orthopedics	317 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Stroke	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Surgery	52 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Unknown	8 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Oncotherapy	1 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatrics	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Psychodiagnosis medical	1 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Comprehensive medical care	3 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Rheumatology	2 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Breast and thyroid surgery	1 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Allergy	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Pediatric cardiology	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiology	465 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Palliative care	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gastroenterology	26 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology	2 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Gynecology	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Urology	15 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory medicine	18 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Dermatology	3 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hematology & medical Oncology	1 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Cardiovascular internal medicine	301 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Hemodialysis	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Respiratory	17 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Diabetes	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Neuropathic internal medicine	74 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Nephrology	7 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Radiology	0 Participants
Edoxaban	Baseline Characteristics: Speciality of Prescribers of OAC	Internal medicine	654 Participants

Secondary

Baseline Characteristics: Year of Initiating Treatment

Baseline characteristics of patients in each treatment group: year of initiating treatment

Time frame: Day 1

Population: eligible patients prescribed dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban as the first OAC

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Dabigatran	Baseline Characteristics: Year of Initiating Treatment	2011/3/14-2012/2/29	404 Participants
Dabigatran	Baseline Characteristics: Year of Initiating Treatment	2012/3/1-2013/2/28	1259 Participants
Dabigatran	Baseline Characteristics: Year of Initiating Treatment	2013/3/1-2014/2/28	1081 Participants
Dabigatran	Baseline Characteristics: Year of Initiating Treatment	2014/3/1-2015/2/28	1019 Participants
Dabigatran	Baseline Characteristics: Year of Initiating Treatment	2015/3/1-2016/2/29	919 Participants
Dabigatran	Baseline Characteristics: Year of Initiating Treatment	2016/3/1-2016/6/30	254 Participants
Warfarin	Baseline Characteristics: Year of Initiating Treatment	2015/3/1-2016/2/29	3217 Participants
Warfarin	Baseline Characteristics: Year of Initiating Treatment	2016/3/1-2016/6/30	1027 Participants
Warfarin	Baseline Characteristics: Year of Initiating Treatment	2011/3/14-2012/2/29	1138 Participants
Warfarin	Baseline Characteristics: Year of Initiating Treatment	2013/3/1-2014/2/28	2292 Participants
Warfarin	Baseline Characteristics: Year of Initiating Treatment	2014/3/1-2015/2/28	2808 Participants
Warfarin	Baseline Characteristics: Year of Initiating Treatment	2012/3/1-2013/2/28	2002 Participants
Apixaban	Baseline Characteristics: Year of Initiating Treatment	2014/3/1-2015/2/28	3455 Participants
Apixaban	Baseline Characteristics: Year of Initiating Treatment	2015/3/1-2016/2/29	5634 Participants
Apixaban	Baseline Characteristics: Year of Initiating Treatment	2011/3/14-2012/2/29	0 Participants
Apixaban	Baseline Characteristics: Year of Initiating Treatment	2013/3/1-2014/2/28	188 Participants
Apixaban	Baseline Characteristics: Year of Initiating Treatment	2012/3/1-2013/2/28	0 Participants
Apixaban	Baseline Characteristics: Year of Initiating Treatment	2016/3/1-2016/6/30	2109 Participants
Rivaroxaban	Baseline Characteristics: Year of Initiating Treatment	2014/3/1-2015/2/28	2182 Participants
Rivaroxaban	Baseline Characteristics: Year of Initiating Treatment	2012/3/1-2013/2/28	175 Participants
Rivaroxaban	Baseline Characteristics: Year of Initiating Treatment	2013/3/1-2014/2/28	1868 Participants
Rivaroxaban	Baseline Characteristics: Year of Initiating Treatment	2016/3/1-2016/6/30	1231 Participants
Rivaroxaban	Baseline Characteristics: Year of Initiating Treatment	2015/3/1-2016/2/29	3302 Participants
Rivaroxaban	Baseline Characteristics: Year of Initiating Treatment	2011/3/14-2012/2/29	0 Participants
Edoxaban	Baseline Characteristics: Year of Initiating Treatment	2015/3/1-2016/2/29	1289 Participants
Edoxaban	Baseline Characteristics: Year of Initiating Treatment	2013/3/1-2014/2/28	29 Participants
Edoxaban	Baseline Characteristics: Year of Initiating Treatment	2012/3/1-2013/2/28	32 Participants
Edoxaban	Baseline Characteristics: Year of Initiating Treatment	2016/3/1-2016/6/30	752 Participants
Edoxaban	Baseline Characteristics: Year of Initiating Treatment	2014/3/1-2015/2/28	158 Participants
Edoxaban	Baseline Characteristics: Year of Initiating Treatment	2011/3/14-2012/2/29	8 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Treatment Pattern of Oral Anticoagulants (OAC) in Japan

Conditions

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Patients by Each Type of Study-target OAC Drug Prescribed for New Users of Anticoagulants With NVAF

Number of Patients Prescribed OAC Drug Apixaban by Dosage

Number of Patients Prescribed OAC Drug Dabigatran by Dosage

Number of Patients Prescribed OAC Drug Edoxaban by Dosage

Number of Patients Prescribed OAC Drug Rivaroxaban by Dosage

Number of Patients Prescribed OAC Drug Warfarin by Dosage

Baseline Characteristics: AF Risk Score

Baseline Characteristics: Age

Baseline Characteristics: Concomitant Medication

Baseline Characteristics: Gender

Baseline Characteristics: History of Disease

Baseline Characteristics: History of Hospitalization

Baseline Characteristics: Speciality of Prescribers of OAC

Baseline Characteristics: Year of Initiating Treatment